GlassScriptPhysician profile
Ariel G Ton
NPI 1134120355
$7,685.53
in general payments reported to CMS, 2019-2025
43 companies · $1,183 in 2025
The $1,183 reported for 2025 was more than what 87% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $988 · 2020: $841 · 2021: $1,168 · 2022: $1,311 · 2023: $1,162 · 2024: $1,033 · 2025: $1,183.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,378.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,378.23 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $1,203.33 | 2019-2025 | Repatha, Otezla, Evenity |
| Astrazeneca Pharmaceuticals LP | $781.48 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Novo Nordisk INC | $615.93 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Pfizer INC. | $566.61 | 2019-2025 | |
| Lilly USA, LLC | $515.82 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Merck Sharp & Dohme LLC | $451.89 | 2019-2023 | Belsomra, Verquvo, Steglatro |
| Daiichi Sankyo INC. | $284.60 | 2019-2023 | Injectafer |
| Astellas Pharma US INC | $262.47 | 2019-2025 | Veozah |
| Kowa Pharmaceuticals America, INC. | $257.15 | 2019-2023 | Livalo, Seglentis |
| Abbott Laboratories | $255.53 | 2022-2025 | Freestyle Libre 3 |
| Amarin Pharma, INC. | $244.39 | 2019-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $216.88 | 2021-2025 | |
| Glaxosmithkline, LLC. | $208.27 | 2021-2025 | Shingrix, Arexvy, Trelegy Ellipta |
| Boehringer Ingelheim Pharmaceuticals, INC. | $163.28 | 2019-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $152.65 | 2020-2024 | Xifaxan |
Show all 43 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $151.64 | 2021-2022 | |
| Esperion Therapeutics, INC. | $134.54 | 2020-2025 | Nexletol |
| Janssen Pharmaceuticals, INC | $125.84 | 2019-2021 | |
| Sanofi-Aventis U.S. LLC | $117.45 | 2019-2022 | |
| Mylan Specialty L.P. | $100.33 | 2021-2023 | Yupelri |
| Allergan, INC. | $79.87 | 2019-2020 | |
| Dexcom, INC. | $72.60 | 2024-2025 | Dexcom G6 Transmitter |
| Inogen, INC. | $66.31 | 2023 | Inogen One G5 Oxygen Concentrator - Bluetooth |
| Corcept Therapeutics | $59.40 | 2023-2025 | Korlym |
| Sumitomo Pharma America, INC. | $57.56 | 2024-2025 | Gemtesa |
| Novartis Pharmaceuticals Corporation | $54.82 | 2022-2024 | |
| Biohaven Pharmaceutical Holding Company LTD. | $53.28 | 2022 | |
| Xeris Pharmaceuticals, INC. | $51.58 | 2024 | Keveyis |
| Shield Therapeutics INC | $46.24 | 2025 | |
| Ibsa Pharma INC. | $40.43 | 2021-2025 | Tirosint, Licart, Flector |
| Avanir Pharmaceuticals, INC. | $35.04 | 2019 | |
| Intuitive Surgical, INC. | $33.43 | 2019 | |
| Itamar Medical INC | $30.57 | 2024 | Watchpatone |
| Nevro Corp. | $24.26 | 2022 | |
| Boston Scientific Corporation | $22.96 | 2025 | Watchman Access System |
| Organogenesis INC. | $22.42 | 2023 | Puraply |
| Horizon Therapeutics Plc | $20.83 | 2019 | |
| Vifor Pharma, INC. | $20.46 | 2022 | |
| Abiomed | $20.37 | 2025 | |
| Arbor Pharmaceuticals, INC. | $17.89 | 2022 | |
| Paratek Pharmaceuticals, INC. | $17.10 | 2023 | Nuzyra |
| Idorsia Pharmaceuticals US INC | $16.50 | 2023 | Quviviq |
| Takeda Pharmaceuticals U.S.A., INC. | $11.53 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ariel Ton listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.